采用手术及辅助治疗的原发性心脏平滑肌肉瘤的两年生存率
Two years survival of primary cardiac leiomyosarcoma managed by surgical and adjuvant therapy.
作者信息
Behi K, Ayadi M, Mezni E, Meddeb K, Mokrani A, Yahyaoui Y, Ksontini F, Rais H, Chrait N, Mezlini A
机构信息
Medical Oncology Department, Salah Azaeiz Institute, Tunis, Tunisia.
出版信息
Clin Sarcoma Res. 2017 Mar 9;7:5. doi: 10.1186/s13569-017-0069-3. eCollection 2017.
BACKGROUND
Cardiac tumors are a very rare entity. Leiomyosarcoma represents less than 1% of cases.
CASE PRESENTATION
a 51-year-old woman diagnosed with primary left atrium leiomyosarcoma. She was treated by optimal surgery and adjuvant chemotherapy. She is still alive after a follow-up of 24 months without evidence of local or distant recurrence.
CONCLUSIONS
Cardiac leiomyosarcoma is a rare tumor with a dismal prognosis. Surgery is the mainstay of treatment. Adjuvant treatment is still controversial.
背景
心脏肿瘤是一种非常罕见的疾病。平滑肌肉瘤占病例的比例不到1%。
病例报告
一名51岁女性被诊断为原发性左心房平滑肌肉瘤。她接受了最佳手术和辅助化疗。随访24个月后她仍然存活，没有局部或远处复发的迹象。
结论
心脏平滑肌肉瘤是一种罕见肿瘤，预后不佳。手术是主要治疗方法。辅助治疗仍存在争议。
Zotero 插件